Vamorolone

Vamorolone
Clinical data
Trade names	Agamree
Other names	VBP; VBP-15; 17α,21-Dihydroxy-16α-methylpregna-1,4,9(11)-triene-3,20-dione
AHFS/Drugs.com	Monograph
MedlinePlus	a624005
License data	US DailyMed: Vamorolone;
Routes of; administration	By mouth
ATC code	H02AB18 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name (8S,10S,13S,14S,16R,17R)-17-Hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one;
CAS Number	13209-41-1;
PubChem CID	3035000;
DrugBank	DB15114;
ChemSpider	2299335;
UNII	8XP29XMB43;
KEGG	D11000;
ChEBI	CHEBI:228304;
ChEMBL	ChEMBL2348780;
CompTox Dashboard (EPA)	DTXSID60927527 ;
ECHA InfoCard	100.032.874
Chemical and physical data
Formula	C22H28O4
Molar mass	356.462 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C3=CC[C@@]2([C@]1(C(=O)CO)O)C)C;
	InChI InChI=1S/C22H28O4/c1-13-10-18-16-5-4-14-11-15(24)6-8-20(14,2)17(16)7-9-21(18,3)22(13,26)19(25)12-23/h6-8,11,13,16,18,23,26H,4-5,9-10,12H2,1-3H3/t13-,16-,18+,20+,21+,22+/m1/s1; Key:ZYTXTXAMMDTYDQ-DGEXFFLYSA-N;

Vamorolone, sold under the brand name Agamree, is a synthetic corticosteroid, which is used for the treatment of Duchenne muscular dystrophy. It is taken by mouth. It is a dual atypical glucocorticoid and antimineralocorticoid.

The most common adverse reactions include cushingoid features, psychiatric disorders, vomiting, increased weight, and vitamin D deficiency.

Vamorolone was approved for medical use in the United States in October 2023, and in the European Union in December 2023.